Guideline for managing patients on Dabigatran (Pradaxa ) Statewide
|
|
- Ambrose Sanders
- 8 years ago
- Views:
Transcription
1 Guideline for managing patients on Dabigatran (Pradaxa ) Statewide Custodian: Medication Safety, Medicines Regulation and Quality medicationsafety@health.qld.gov.au Developed by Medication Safety, Medicines Regulation and Quality and the Anticoagulant Working Party (membership includes representation from General Practice Queensland, Sullivan Nicolaides Pathology, QML Pathology) Version no: 2.0 Applicable To: All Queensland Health staff involved with management of patients who present to hospital on dabigatran Approval Date: 21/05/ Purpose This Guideline is intended to assist clinicians with the management of patients who are admitted to hospital already taking dabigatran. It is not intended as a guideline for initiation of treatment with dabigatran. Haematology consultation is advisable in most clinical situations. Within the first two years of dabigatran being on the Australian market there were numerous incident reports of haemorrhage and deaths in Queensland, nationally and internationally. This prompted the need for a specific guideline for the management of patients presenting to hospital who are already taking the drug. Effective Date: 21/05/2013 Next Review Date: 21/05/2015 Authority: Approving Officer Signed Name Dr Sue Ballantyne Director, Medicines Regulation and Quality Supersedes: Guidelines for managing patients on Dabigatran (Pradaxa ) who present to hospital (v1.0, 2011) 2. Scope This Guideline provides information for all Queensland Health employees (permanent, temporary and casual) and all organisations and individuals acting as its agents (including Visiting Medical Officers and other partners, contractors, consultants and volunteers). 3. Related documents Queensland Health List of Approved Medicines Statewide Heparin Intravenous Infusion Order and Administration Adult form Guidelines for Anticoagulation Using Warfarin Guidelines for Managing Patients on Rivaroxaban (Xarelto ) Key Words: dabigatran, anticoagulant, Pradaxa Accreditation References: EQuIP and other criteria and standards Version No.: 2.0; Effective From: 21/05/2013 Page 1 of 12
2 Disclaimer This guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. Information in this guideline is current at time of publication. The Department of Health, Queensland Government does not accept liability to any person for loss or damage incurred as a result of reliance upon the material contained in this guideline. Clinical material offered in this guideline does not replace or remove clinical judgement or the professional care and duty necessary for each specific patient case. Clinical care carried out in accordance with this guideline should be provided within the context of locally available resources and expertise. This Guideline does not address all elements of standard practice and assumes that individual clinicians have the responsibility to: Discuss care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes the use of interpreter services where necessary. Advise consumers of their choice and ensure informed consent is obtained. Provide care within scope of practice, meet all legislative requirements and maintain standards of professional conduct. Apply standard precautions and additional precautions as necessary, when delivering care. Document all care in accordance with mandatory and local requirements. Guideline for Managing Patients on Dabigatran (Pradaxa ) Published by the State of Queensland (Queensland Health), May, 2013 State of Queensland (Queensland Health) 2013 This work is licensed under a Creative Commons Attribution Non-Commercial Share Alike 3.0 Australia licence. In essence, you are free to copy, communicate and adapt the work for non-commercial purposes, as long as you attribute Medicines Regulation and Quality, Department of Health, Queensland Government, you distribute any derivative work only under this licence and you abide by the licence terms. To view a copy of this licence, visit For further information contact Medication Safety Officer, Medicines Regulation and Quality, Locked Bag 21, Fortitude Valley BC Qld 4006, MedicationSafety@health.qld.gov.au. For permissions beyond the scope of this licence contact: Intellectual Property Officer, Department of Health, GPO Box 48, Brisbane Qld 4001, ip_officer@health.qld.gov.au, phone (07) Version No.: 2.0; Effective From: 21/05/2013 Page 2 of 12
3 4. Guideline 4.1 Indications Queensland Health: Guideline for managing patients on Dabigatran (Pradaxa ) Dabigatran is an oral direct thrombin inhibitor. It is available as 75 mg, 110 mg and 150 mg tablets. It is not currently listed on the Queensland Health List of Approved Medicines (LAM). Table A: Approved indications for dabigatran TGA approved indications PBS listed Prevention of venous thromboembolic (VTE) events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip and knee replacement) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke Yes (except 150 mg) No TGA = Therapeutic Goods Administration; PBS = Pharmaceutical Benefits Scheme Dabigatran is primarily renally excreted and is contraindicated if creatinine clearance (CrCl) is less than 30 ml/min. Note: Calculation of CrCl should be determined using ideal body weight with the Cockcroft-Gault equation as it is more accurate than egfr for patients who are elderly or who have low body weight (see online calculators available locally, on QHEPS or etg Complete). Risk factors for adverse events with dabigatran include age older than 75 years, low body weight (less than 50 kg), and moderate or severe renal impairment (CrCl less than 50 ml/min). Version No.: 2.0; Effective From: 21/05/2013 Page 3 of 12
4 4.2 Monitoring / Pathology testing There is currently no assay available for dabigatran levels in Queensland Health facilities. Advice should be sought from local laboratories on availability of coagulation tests. Monitoring with International Normalised Ratio (INR) is not recommended. The following tests are qualitative indicators and can be influenced by concomitant use of other anticoagulants: Activated partial thromboplastin time (APTT) is moderately sensitive to dabigatran, but it becomes increasingly insensitive with higher levels. A trough (when the next dose is due) APTT of 1.5 times the baseline value is seen with 150 mg twice daily of dabigatran in patients with normal renal function. Trough APTT values greater than 80 seconds are associated with increased bleeding risk. Thrombin time (TT) is very sensitive to dabigatran, and a normal TT excludes the presence of significant dabigatran levels but is not useful for monitoring or dose adjustment. Routine testing is generally not conducted during treatment with dabigatran because it has a predictable pharmacokinetic profile enabling a fixed-dose regimen. Laboratory testing is currently limited but may be helpful in the following situations: the peri-operative setting acute coronary syndrome (ACS) in the event of bleeding or recurrent thrombosis elderly patients due to higher risk of bleeding when renal function is deteriorating or if renal impairment with CrCl less than 50_mL/min when parenteral anticoagulants are being considered for a patient taking dabigatran patients with extremes of body weight because low body weight has a high bleeding risk and obesity may have poor efficacy patients on potentially interacting medications (i.e. concomitant administration of strong inducers or inhibitors of P-glycoprotein) in case of overdose or if there are concerns about compliance. Version No.: 2.0; Effective From: 21/05/2013 Page 4 of 12
5 4.3 Drug interactions Thrombolytic agents or antiplatelet agents (e.g. aspirin, clopidogrel, prasugrel, ticagrelor, ticlopidine): Concomitant administration of these agents with dabigatran is a relative contraindication as dual therapy is associated with higher risks of bleeding and anaemia, especially if other risk factors (see section 4.1) are present. Other Anticoagulants: Concomitant administration is not recommended with rivaroxaban, warfarin, heparin, or low molecular weight heparin. Non-steroidal anti-inflammatory drugs (NSAIDs): Monitor for risks of bleeding if dabigatran used with NSAIDs, especially those with half-lives greater than 12 hours (e.g. naproxen, piroxicam). NSAIDs with short half-lives less than 12 hours (e.g. ibuprofen) have not been shown to be associated with increased bleeding risk. Inhibitors of P-glycoprotein efflux transporter: The prodrug dabigatran exilate is a substrate for the P-glycoprotein efflux transporter. Avoid use in combination with the following inhibitors which may increase the levels of dabigatran. azoles (e.g. ketoconazole, itraconazole) calcium channel blockers (e.g. diltiazem, nifedipine, verapamil) immunosuppressants (e.g. cyclosporine, tacrolimus) macrolides (e.g. clarithromycin, erythromycin) protease inhibitors (e.g. ritonavir, saquinavir) others (e.g. amiodarone, dipyridamole, hydrocortisone, progesterone, propranolol, quinine, tamoxifen). Inducers of P-glycoprotein efflux transporter: Avoid concomitant use of dabigatran with the following inducers of the P-glycoprotein efflux transporter which may reduce levels of dabigatran. carbamazepine rifampicin St John s Wort. Version No.: 2.0; Effective From: 21/05/2013 Page 5 of 12
6 4.4 Management of bleeding Currently, there is no known clinically proven antidote for dabigatran. In a human volunteer study, prothrombin complex concentrates did not normalise the prolonged times of the relevant coagulation tests. Vitamin K and fresh frozen plasma infusion have not been shown to be effective. The effect of factor VIIa (Novoseven ) is currently uncertain. Dabigatran associated bleeding If a patient is bleeding, discontinue dabigatran therapy and investigate for site of bleeding. Initiate symptomatic treatment and optimise renal function. Review all medications and discontinue all anticoagulants, anti-platelet agents and NSAIDs. Check for possible drug interactions (see section 4.3). For patients who have had warfarin in the last four days, administer 10 mg vitamin K intravenously. Check coagulation screen (APTT, TT and fibrinogen assay); indicate time of last dose on request form. Check full blood count, renal function and electrolytes (including calcium). Organise blood group and hold, and blood group antibody screen. Mild bleeding Moderate bleeding # Severe to life threatening bleeding* Withhold next dose Discontinue dabigatran. Implement all measures for of dabigatran or Consult Haematology moderate bleeding. discontinue Service. Consider anti-fibrinolytic agent treatment as Mechanical compression, or tranexamic acid IV mg/kg, appropriate. consider surgical followed by a continuous infusion at Apply local intervention or wound 1 mg/kg/hr until bleeding is under measures and treat packing. control. any aggravating factors. Administer fluid replacement to maintain good urine output as dabigatran is renally excreted. Consider platelets if levels less than x 10 9 /L or patient on anti-platelet agent. Administer oral activated charcoal if dabigatran ingested in last two hours. Recombinant factor VIIa (Novoseven ) IV bolus 50 microg/kg may be trialled if critical. Repeat if necessary with Haematology guidance. Φ Note factor VIIa half-life is significantly shorter than dabigatran and so this will require further close monitoring of the patient. Haemodialysis (especially if renal failure present) may remove approximately 60% of dabigatran. # Moderate bleeding: non-trivial bleeding with a reduction in haemoglobin of less than 20 g/l, or requiring transfusion of less than two units of red blood cells. * Severe to Life-threatening bleeding: bleeding with a reduction in haemoglobin of greater than or equal to 20 g/l, or requiring transfusion of greater than or equal to two units of red blood cells, or involving a critical site. There is limited evidence of the clinical benefit for tranexamic acid in this setting and treatment should not delay resuscitation and adequate factor replacement. Φ NB: Individual Patient Approval should be obtained as per Hospital and Health Service or local procedure for recombinant factor VIIa For the management of life-threatening bleeding and coagulopathy in non-haemophiliac patients who have failed to respond to conventional therapy. (See Appendix 9 of the LAM) Version No.: 2.0; Effective From: 21/05/2013 Page 6 of 12
7 4.5 Management peri-operatively of patients admitted to hospital on dabigatran Semi-acute or elective surgery Assess the risk of bleeding against the risk of thrombosis as dabigatran may not need to be discontinued for minor procedures. If dabigatran needs to be withheld, plan ahead as there is no known treatment available for immediate reversal. Consider bridging anticoagulant therapy if there is a high risk of thrombosis (see section 4.6). As dabigatran is primarily renally excreted, renal function will determine the withholding time prior to surgery and this should be checked pre-admission. The patient should be advised when to withhold dabigatran pre-operatively. In situations where complete haemostasis is required, APTT and TT should be checked pre-operatively. Table B: Discontinuation of dabigatran prior to surgery Renal function (CrCl, ml/min) NB. Use Cockcroft-Gault equation with ideal body weight (see section 4.1) Dabigatran half-life (range) Withholding time of dabigatran prior to surgery after last dose Low bleeding risk High bleeding risk Ψ Greater than (11-22) hours 48 hours 5 days (12-34) hours 48 hours 5 days (13-23) hours At least 72 hours 5 days Equal to or less than (22-35) hours 5 days do not restart Greater than 5 days do not restart Ψ Types of surgery associated with high risk of bleeding include cardiac surgery, neurosurgery, abdominal surgery, surgery involving a major organ, or in major surgery where complete haemostasis may be required. Other procedures such as spinal anaesthesia may require complete haemostasis. Other risk factors for bleeding include advancing age, co-morbidities (e.g. major cardiac, respiratory or liver disease) and concomitant use of anti-platelet therapy. Urgent surgery Stop dabigatran. Administer oral activated charcoal if dabigatran ingested in the last two hours. Check full blood count, electrolytes (including calcium), renal function and coagulation screen (APTT, TT and fibrinogen assay); indicate time of last dabigatran dose on request form. Consider delaying surgery, if appropriate, until coagulation screen is normal or until sufficient time for drug clearance (four half-lives). Where urgent life-saving surgery cannot be delayed, consult with Haematology Service over measures to control bleeding perioperatively. Epidural and spinal anaesthesia are contraindicated. Cross-match blood. Recommendations regarding epidural and spinal catheter Epidural and spinal anaesthesia are contraindicated unless dabigatran has been eliminated as indicated by a normal TT. Dabigatran should not be recommenced in patients who have an epidural or spinal catheter in place. Dabigatran should not be restarted within 24 hours of removal of spinal or epidural catheter; a longer delay should be considered if there are multiple punctures or traumatic insertion of spinal or epidural catheter. Version No.: 2.0; Effective From: 21/05/2013 Page 7 of 12
8 Restarting dabigatran after surgery Discuss with Haematology Service based on nature of surgery, haemostatic state and urgency of restarting anticoagulant therapy. Do not restart dabigatran in severe renal impairment (i.e. if CrCl is less than 30 ml/min). In elective surgery where haemostasis is satisfactory, it is suggested that dabigatran is restarted after at least 12 hours if the surgeon considers it safe to do so. If haemostasis is not satisfactory and clinically significant bleeding is present, a delay in restarting dabigatran is appropriate. Consider using an alternative reversible anticoagulant (e.g. unfractionated heparin) if the risk of thrombosis is greater than the risk of wound bleeding. Version No.: 2.0; Effective From: 21/05/2013 Page 8 of 12
9 4.6 Bridging or switching to or from other anticoagulants Conversion from dabigatran to a parenteral anticoagulant Table C: Converting dabigatran to parenteral anticoagulants Creatinine clearance (CrCl) APTT 12 hours after last dabigatran dose Instructions Greater than or equal to 30 ml/min Less than 30 ml/min # Less than 60 seconds Greater than 60 seconds Less than 60 seconds Greater than 60 seconds Start treatment dose of low molecular weight heparin (LMWH) when next dose of dabigatran would have been due. OR Start unfractionated heparin (UFH)* intravenous infusion without a bolus. Measure APTT six hours after infusion has started, then as per the Queensland Health Heparin Intravenous Infusion Order and Administration Adult form guidelines. Repeat APTT every six hours until APTT is less than 60 seconds, then: Start treatment dose of low molecular weight heparin (LMWH) when next dose of dabigatran would have been due. OR Start unfractionated heparin (UFH)* intravenous infusion without a bolus. Measure APTT six hours after infusion has started, then as per the Queensland Health Heparin Intravenous Infusion Order and Administration Adult form guidelines. Start unfractionated heparin (UFH)* intravenous infusion without a bolus. Measure APTT six hours after infusion has started, then as per the Queensland Health Heparin Intravenous Infusion Order and Administration Adult form guidelines. Repeat APTT every six hours until APTT is less than 60 seconds, then: Start unfractionated heparin (UFH)* intravenous infusion without a bolus. Measure APTT six hours after infusion has started, then as per the Queensland Health Heparin Intravenous Infusion Order and Administration Adult form guidelines. * Note: Loading doses of UFH should not be given. The Queensland Health Heparin Intravenous Infusion Order and Administration Adult form should only be used as a guide for dose adjustment. # Note: Dabigatran is contraindicated if CrCl is less than 30 ml/min. Do not restart. Conversion from a parenteral anticoagulant to dabigatran Check renal function prior to re-starting dabigatran. If renal impairment, dabigatran may require dose adjustment or should not be used, depending on its indication (avoid if CrCl is less than 30 ml/min). For conversion from an UFH infusion to dabigatran, start dabigatran when infusion ceased. For conversion from low molecular weight heparin (LMWH) such as enoxaparin to dabigatran, start dabigatran 12 hours after the last dose of LMWH. Version No.: 2.0; Effective From: 21/05/2013 Page 9 of 12
10 Conversion from dabigatran to warfarin For conversion from dabigatran to warfarin, adjust the starting time of warfarin based on renal function (see Table D) and start dosing as per the Queensland Health Guidelines for Anticoagulation Using Warfarin - Adult. As dabigatran can contribute to an elevated INR, the INR will better reflect the effect of warfarin after dabigatran has been ceased for two days. If patient has previously been on warfarin restart on usual dose. Table D: Converting dabigatran to warfarin Creatinine clearance (CrCl) Low risk of thrombosis Options for conversion High risk of thrombosis Greater than or equal to 50 ml/min Stop dabigatran and start warfarin at the next standard administration time. Start warfarin at next standard administration time three days before discontinuing dabigatran 31 to 50 ml/min Stop dabigatran and start warfarin at the next standard administration time. Start warfarin for two days before discontinuing dabigatran Less than or equal to 30 ml/min # Stop dabigatran and start warfarin at the next standard administration time. Stop dabigatran and start warfarin at next standard administration time. # Note: Dabigatran is contraindicated if CrCl is less than 30 ml/min. Do not restart. Conversion from warfarin to dabigatran Check renal function prior to re-starting dabigatran. If renal impairment, dabigatran may require dose adjustment or should not be used, depending on its indication (avoid if CrCl is less than 30 ml/min). For conversion from warfarin to dabigatran, discontinue warfarin and start dabigatran when INR is below two. 4.7 Venous Thromboembolism (VTE) prophylaxis Do not commence pharmacological VTE prophylaxis (e.g. heparin, enoxaparin, dalteparin) if patient is taking dabigatran. If dabigatran is ceased, and VTE prophylaxis is indicated, start pharmacological prophylaxis when APTT is less than 60 seconds. Version No.: 2.0; Effective From: 21/05/2013 Page 10 of 12
11 4.8 Acute coronary syndrome (ACS) There is currently no published literature available for ACS management in patients who are on dabigatran, rivaroxaban or apixaban. The following information is suggested guidance only and it may be modified in the future depending on accumulating clinical experience. Further advice should be sought from a cardiologist. Note: For patients with stents requiring dual antiplatelet therapy, dabigatran should only be considered by a cardiologist. Table E: Acute coronary syndrome management in patients on dabigatran ST Elevation Myocardial Infarction (STEMI) For parenteral anticoagulation for ACS in dabigatran treated patients, unfractionated heparin (UFH) is preferred to low molecular weight heparin. For patients receiving dabigatran, primary percutaneous coronary intervention (PCI) is preferred (if available) to thrombolysis. The decision to thrombolyse should be based on an assessment of the perceived benefit (e.g. anterior versus inferior myocardial infarction, time to presentation) versus the perceived risk of a bleeding complication (e.g. elderly, reduced renal function, presence of other relative contraindications). If thrombolysis is administered, do not start UFH within 12 hours of last dabigatran dose or longer if impaired renal function (see likely half life-lives with renal impairment in Table B). Loading doses of UFH should not be given. See Table C, section 4.6 for information on UFH dosing. Non-ST Elevation Acute Coronary Syndrome (NSTEACS) (e.g. Non-ST Elevation Myocardial Infarction (NSTEMI) and Unstable Angina) For parenteral anticoagulation for ACS in dabigatran treated patients, unfractionated heparin (UFH) is preferred to low molecular weight heparin. Do not start UFH within 12 hours of the last dose of dabigatran or longer if impaired renal function (see likely half life-lives with renal impairment in Table B). Loading doses of UFH should not be given. See Table C, section 4.6 for information on UFH dosing. Version No.: 2.0; Effective From: 21/05/2013 Page 11 of 12
12 5. Definition of Terms Definitions of key terms are provided below. Term Definition / Explanation / Details TGA Therapeutic Goods Administration PBS Pharmaceutical Benefits Scheme LAM Queensland Health List of Approved Medicines CrCl Creatinine clearance which is an indicator for renal function INR International normalised ratio APTT Activated partial prothrombin time TT Thrombin time ACS Acute coronary syndrome NSAIDs Non-steroidal anti-inflammatory drugs LMWH Low molecular weight heparin UFH Unfractionated heparin VTE Venous thromboembolism STEMI ST elevation myocardial infarction NSTEACS Non-ST elevation acute coronary syndrome 6. References and Suggested Reading References are available on request. 7. Consultation (optional) Key stakeholders who reviewed this version are: Statewide General Medicine Clinical Network Statewide Cardiac Clinical Network 8. Guideline Revision and Approval History Version Modified by Amendments authorised by Approved by No. 1.0 Sarah Mathers Queensland Health Dr Julie Stokes Statewide Anticoagulant Working Party 2.0 Sarah Mathers Queensland Health Statewide Anticoagulant Working Party Dr Sue Ballantyne Version No.: 2.0; Effective From: 21/05/2013 Page 12 of 12
Guideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto )
Guideline [Optional heading here. Change font size to suit] Document Number # QH-GDL-950:2014-2 Guideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto ) 1.
More informationGuideline for Anticoagulation and Prophylaxis Using Low Molecular Weight Heparin (LMWH) in Adult Inpatients
Guideline [Optional heading here. Change font size to suit] Document Number # QH-GDL-951:2015 Guideline for Anticoagulation and Prophylaxis Using Low Molecular Weight Heparin (LMWH) in Adult Inpatients
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationUse of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationDr Gordon Royle Haematologist, Middlemore Hospital
The New Oral Anticoagulants (NOACs) Dr Gordon Royle Haematologist, Middlemore Hospital Disclaimers Boehringer-Ingelheim Bayer Sanofi Douglas Pharmaceuticals Preventing disasters: lessons learned A cautionary
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationNHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016
More informationExperience matters: Practical management in your hospital
Experience matters: Practical management in your hospital Dr AGG Turpie McMaster University, Hamilton, ON, Canada Disclosures AGG Turpie has acted as a consultant for Bayer HealthCare, Janssen, Sanofi-Aventis,
More informationQUICK REFERENCE. Mary Cushman 1 Wendy Lim 2 Neil A Zakai 1. University of Vermont 2. McMaster University
QUICK REFERENCE Clinical Practice Guide on Antithrombotic Drug Dosing and Management of Antithrombotic Drug- Associated Bleeding Complications in Adults February 2014* Mary Cushman 1 Wendy Lim 2 Neil A
More informationClinical Guideline N/A. November 2013
State if the document is a Trust Policy/Procedure or a Clinical Guideline Clinical Guideline Document Title: Document Number 352 Version Number 1 Name and date and version number of previous document (if
More informationDr Gordon Royle Haematologist, Middlemore Hospital
The New Oral Anticoagulants (NOACs) Dr Gordon Royle Haematologist, Middlemore Hospital Disclaimers Boehringer-Ingelheim Bayer Sanofi Douglas Pharmaceuticals Preventing disasters: lessons learned A cautionary
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 06/06/2012 Review Date 06/06/2014 Version 1.1 EQIA Yes /
More informationNORTH WEST LONDON GUIDANCE ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION
North West London CardioVascular & Stroke Network NORTH WEST LONDON GUIDANCE ON ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION Key Messages 1. Efforts should be made to identify patients with Atrial
More informationDABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationDorset Medicines Advisory Group
Shared Care Guideline for prescribing rivaroxaban in the prevention of adverse outcomes after acute management of acute coronary syndrome in adults INDICATION In accordance with NICE TA335 rivaroxaban
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationRivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement surgery
for preventing venous thromboembolism after hip or knee replacement surgery (riv-ah-rocks-ah-ban) Summary Rivaroxaban is an oral anticoagulant and the first direct factor Xa inhibitor. Rivaroxaban has
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationUncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser
Acute Sector NHS Grampian Staff Local Treatment Protocol For Venous Thromoboembolic Prophylaxis Using Rivaroxaban 10mg Tablets In Adult Patients Undergoing Elective Hip Or Knee Replacement Surgery. Lead
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationMore information for patients and caregivers can be accessed at http://www.xarelto-us.com/.
Janssen Research & Development Submits Application to U.S. FDA for XARELTO (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome RARITAN, DECEMBER 29, 2011 -
More informationNWMIC Medicines FAQ. New oral anticoagulants (NOACs) and management of dental patients - Dabigatran, rivaroxaban and apixaban.
NWMIC Medicines FAQ New oral anticoagulants (NOACs) and management of dental patients - Date prepared: May 2013, updated November 2013 Summary In primary care; Consider liaising with the local hospital
More informationRivaroxaban (Xarelto ) by
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationAnticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
More informationSession 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationDabigatran and Its Effect on Bleeding Risk
South West Essex Dabigatran Shared Care Guideline (SCG) Dabigatran SCG for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation Introduction Indication and Licensing
More informationClinical guide to managing patients treated with Pradaxa
Clinical guide to managing patients treated with Pradaxa Updated August 2013 Treatment with Pradaxa (dabigatran etexilate) requires no routine laboratory monitoring. 1 Routine coagulation tests (aptt,
More informationDabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationTitle of Guideline. Thrombosis Pharmacist)
Title of Guideline Contact Name and Job Title (author) Guideline for patients receiving Rivaroxaban (Xarelto ) requiring Emergency Surgery or treatment for Haemorrhage Julian Holmes (Haemostasis and Thrombosis
More informationPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip or knee replacement surgery.
PRADAXA (DABIGATRAN ETEXILATE) PRESCRIBER GUIDE FOR PRIMARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS (VTE) FOLLOWING ELECTIVE TOTAL HIP OR KNEE REPLACEMENT SURGERY This guide provides recommendations
More informationEMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults. February, 2013
EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults February, 2013 1 Quick Index To Reversal Recommendations Anti-Platelet Medications Page P2Y12
More informationThrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationNews Release. Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com
News Release Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com Shaun Mickus Phone: 908.927.2416 Mobile: 973.476.7144 smickus@its.jnj.com Investor contacts: Stan
More informationGuidance for prescribing of Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) and Apixaban (Eliquis ) in Patients with Non-Valvular AF
Guidance for prescribing of Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) and Apixaban (Eliquis ) in Patients with Non-Valvular AF Lesley Davey Staffordshire and Lancashire CSU November 2013 (Review November
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationCardiac Diseases and Therapies ATRIAL FIBRILLATION DABIGATRAN CLINICIAN SUMMARY
Mechanism of Action: Direct Thrombin Inhibitor BACKGROUND Dabigatran is a direct thrombin inhibitor (DTI) that is administered orally. It inhibits both free and clot-bound thrombin. It is currently indicated
More informationUSE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:
More informationLAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
More informationNovel Oral Anticoagulants (NOACs) Prescriber Update 2013
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More informationTA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation 1 Name of Commissioning
More informationUpdate on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationHow To Manage An Anticoagulant
PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals, including primary care physicians,
More informationWarfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
More information2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationDabigatran (Pradaxa) for stroke prevention in patients with non-valvular atrial fibrillation (da-big-a-tran)
Dabigatran (Pradaxa) 1 Dabigatran (Pradaxa) for stroke prevention in patients with non-valvular atrial fibrillation (da-big-a-tran) Similar rate of major bleeding to warfarin KEY POINTS Dabigatran is an
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationWhat You Should NOAC About the New Anticoagulants. Dr Calum Young Cardiologist
What You Should NOAC About the New Anticoagulants Dr Calum Young Cardiologist Overview The Burden of AF What s Wrong With Warfarin? The Era of NOACs NOACs in New Zealand Clinical Trials with NOACs Potential
More informationThe new oral anticoagulants & the future of haemostasis laboratory testing. Alcohol: the good, the bad and the ugly
The new oral anticoagulants & the future of haemostasis laboratory testing Emmanuel J Favaloro Diagnostic Haemostasis Laboratory, Institute of Clinical Pathology & Medical Research, ICPMR, Pathology West,
More informationNew oral anticoagulants and antiplatelets: Where do they fit? Meredith Hollinger, PharmD BCPS
New oral anticoagulants and antiplatelets: Where do they fit? Meredith Hollinger, PharmD BCPS Clinical Pharmacy Specialist, Cardiology September 2012 Objectives Describe the mechanisms of action for novel
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationCritical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
More informationSTARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
More informationXARELTO (RIVAROXABAN) PRESCRIBER GUIDE
XARELTO (RIVAROXABAN) PRESCRIBER GUIDE Prescribing information found on pages 22-23 This guide is to be used to support the appropriate use of Xarelto in the following indications: Prevention of stroke
More informationOral Anticoagulants: What s New?
Oral Anticoagulants: What s New? Sallie Young, Pharm.D., BCPS (AQ-Cardiology) Clinical Pharmacy Specialist, Cardiology Penn State Hershey Medical Center syoung1@hmc.psu.edu August 2012 Oral Anticoagulant
More informationPractical guide to Pradaxa in NVAF
Practical guide to Pradaxa in NVAF Pradaxa (dabigatran etexilate) is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and at least one
More informationThe Brave New (Anticoagulant) World
The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA
More informationXARELTO (RIVAROXABAN) PRESCRIBER GUIDE
XARELTO (RIVAROXABAN) PRESCRIBER GUIDE Prescribing information found on pages 16-17 This guide is to be used to support the appropriate use of Xarelto in the following indications: Prevention of stroke
More informationNHS FIFE WIDE POLICY - HAEMATOLOGY MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY
MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY The scope of this guideline is to simplify the management of patients on oral anticoagulation undergoing major and minor surgery.
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More informationManagement of bleeding in emergency situations for patients treated with Pradaxa (dabigatran etexilate)
Management of bleeding in emergency situations for patients treated with Pradaxa (dabigatran etexilate) Updated January 2015 2 3 Management of bleeding in emergency situations for patients treated with
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationMCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
More information2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
More informationPractical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준
Practical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준 Contents Converting to/from rivaroxaban Measuring levels of rivaroxaban Patients potentially at higher risk of bleeding Renal
More informationRivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Implementation of NICE TA 261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Contents 1. Executive summary 2. Introduction
More informationAnticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
More informationNew Oral Anticoagulant Drugs What monitoring if any is required?
New Oral Anticoagulant Drugs What monitoring if any is required? Michelle Williamson Supervising Scientist High Throughput Haematology Pathology Queensland PAH Laboratory Overview Background What new oral
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationRivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists
Rivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists Traffic light classification- Amber 2 specialist initiation Information sheet for Primary Care Prescribers
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationTHE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS
THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS Ingo Ahrens, Christoph Bode Cardiology and Angiology I, Heart Center Freiburg University, Freiburg,
More informationAnticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
More informationSurgery and Anti-Coagulation Agents
CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Pre-admission clinics and surgical wards Personnel involved in surgical pre-assessment
More informationImpact of new (direct) oral anticoagulants in patient blood management
Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationPRADAXA (DABIGATRAN ETEXILATE) PRESCRIBER GUIDE FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
PRADAXA (DABIGATRAN ETEXILATE) PRESCRIBER GUIDE FOR STROKE PREVENTION IN ATRIAL FIBRILLATION This guide provides recommendations for the use of Pradaxa (dabigatran etexilate) in order to minimise the risk
More informationNOAC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions
AC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions FAQ document jointly prepared by NHSGGC Haematology Service & Medicines Infmation On behalf of the Heart MCN
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationReversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug
More informationNHS Tayside Integrated Dental Service Local Guidance. July 2013 Version (v2)
Dental Management of Patients Taking Anticoagulant Drugs Outside a General Hospital Setting NHS Tayside Integrated Dental Service Local Guidance July 2013 Version (v2) Compiled by: G Sime Reviewed by:
More informationDisclosure/Conflict of Interest
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
More informationXARELTO (RIVAROXABAN) EDUCATIONAL PACK FOR 15MG AND 20MG DOSING
XARELTO (RIVAROXABAN) EDUCATIONAL PACK FOR 15MG AND 20MG DOSING NOW UPDATED A N D I N C L U D E S A NEW INDICATION Prevention of stroke and systemic embolism in eligible adult patients with non-valvular
More information